iBio fast-tracking discovery for hard-to-drug targets with precision antibody therapeutics powered by AI and machine learning
February 6, 2024
Biotech firm iBio (NYSEA:IBIO) has incorporated EngageTx, a machine learning-driven technology, into its development roadmap.
In transitioning from CDMO and cGMP biologics manufacturing to a AI-powered biotechnology company, iBio has changed leadership and location as part of their mission to become a stalwart in developing antibodies for hard-to-drug targets
iBio is jockeying for position as a leading player in AI-powered drug discovery while also expanding its immuno-oncology pipeline after closing on the acquisition of multiple assets from its partner, RubrYc Therapeutics.